Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Multiple Cancer Types

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

Disease Sites: Neuroendocrine, Pancreatic

Phase: II

Investigator: Ramirez, Robert

NCTID: NCT05040360

Protocol No: SWOGGIS2104

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Multiple Cancer Types

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Disease Sites: Germ Cell (Pediatrics), Gynecologic, Ovarian

Phase: III

Investigator: Borinstein, Scott

NCTID: NCT03067181

Protocol No: COGAGCT1531

Phase I Open-Label Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

Head/Neck

Disease Sites: Head/Neck

Phase: I

Investigator: Rosenthal, Eben

NCTID:

Protocol No: VICCHNP26039

STAR Trial (Siegel Transcatheter Aortic Valve Replacement in patients with symptomatic severe aortic stenosis)

Disease Sites: Not Available

Phase: N/A

Investigator: Goel, Kashish

NCTID:

Protocol No: VALV0019

Safety and Functional Outcomes Following Laryngeal Transplantation

Head/Neck

Disease Sites: Head/Neck

Phase: N/A

Investigator: Gelbard, Alexander

NCTID:

Protocol No: VICCHN2293

Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)

Head/Neck

Disease Sites: Head/Neck

Phase: Early I

Investigator: Kobayashi, Kenji

NCTID:

Protocol No: VICCHN26044

Expanded Access Program (EAP) for Obecabtagene Autoleucel (Obe-Cel) Out-of-Specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia

Leukemia

Disease Sites: Leukemia

Phase: N/A

Investigator: Oluwole, Olalekan

NCTID:

Protocol No: VICC-CTT25006

A Window of Opportunity Study of Low-Dose Neoadjuvant Nivolumab in Head and Neck Squamous Cell Carcinoma (HNSCC)

Head/Neck

Disease Sites: Head/Neck

Phase: I

Investigator: Rosenthal, Eben

NCTID:

Protocol No: VICCHN25078

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

Neuro-Oncology

Disease Sites: Neuro-Oncology

Phase: Early I

Investigator: Morone, Peter

NCTID:

Protocol No: VICCHN25072

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Multiple Myeloma

This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

Disease Sites: Multiple Myeloma

Phase: II

Investigator: Sengsayadeth, Salyka

NCTID: NCT05972135

Protocol No: VICCPCL24566

Clinical Trial Flowcharts
for Referring Physicians

Clinical Trial Flowcharts
for VICC Staff (VUNetID required)

Clinical Trials Search CTA Inline Referral Form